Literature DB >> 8440913

Histopathologic recognition and grading of dysplastic melanocytic nevi: an interobserver agreement study.

L M Duncan1, M Berwick, J A Bruijn, H R Byers, M C Mihm, R L Barnhill.   

Abstract

Before the controversies surrounding dysplastic melanocytic nevi are resolved, dermatopathologists must be able to reliably distinguish dysplastic nevi from common acquired nevi and malignant melanoma. To establish whether grading of melanocytic dysplasia has any biologic relevance, dermatopathologists must be able to consistently recognize two or more grades of atypia. We studied the concordance among five dermatopathologists for recognition and grading of 60 nevomelanocytic lesions. Ten cases from each of the following categories of melanocytic proliferation were retrieved from the Massachusetts General Hospital files: 1) common melanocytic nevi, 2) melanocytic nevi with features of dysplastic nevi, 3) dysplastic nevi with slight cytologic atypia, 4) dysplastic nevi with moderate cytologic atypia, 5) dysplastic nevi with severe cytologic atypia, and 6) primary malignant melanoma. The slides were reviewed independently; no discussion of diagnostic criteria preceded the review. Overall concordance for diagnosing dysplastic nevi was 77%, with a kappa statistic of 0.55-0.84. Furthermore, in grading dysplastic nevi, experienced dermatopathologists had a concordance ranging from 35% to 58% (kappa value 0.38-0.47). Those with less experience in grading dysplastic nevi had a concordance of 16-65% (kappa value 0.05-0.24). The five observers in this study reliably distinguished dysplastic nevi from common acquired nevi and malignant melanoma. Further refinement of the criteria for grading of nevo-melanocytic dysplasia and experience in grading are critical for accuracy in subcategorization of dysplastic nevi. Consistent, reproducible subcategorization of dysplastic nevi is a requisite before the issue of biologic or prognostic relevance of grading (dysplastic nevi) can be addressed. This study supports the validity of existing criteria for the diagnosis of dysplastic nevi because the problems in diagnosis were at the limits of the spectrum, namely, discrimination of slightly atypical dysplastic nevi from common nevi and severely atypical dysplastic nevi from radial growth phase melanoma.

Entities:  

Mesh:

Year:  1993        PMID: 8440913     DOI: 10.1111/1523-1747.ep12470215

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  16 in total

1.  Histopathological characteristics of small diameter melanocytic naevi.

Authors:  M Braun-Falco; R Hein; J Ring; N S McNutt
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

Review 2.  The dysplastic naevus.

Authors:  W J Mooi
Journal:  J Clin Pathol       Date:  1997-09       Impact factor: 3.411

3.  The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects.

Authors:  Keith Duffy; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2012-07       Impact factor: 11.527

4.  Pathologist characteristics associated with accuracy and reproducibility of melanocytic skin lesion interpretation.

Authors:  David E Elder; Michael W Piepkorn; Raymond L Barnhill; Gary M Longton; Heidi D Nelson; Stevan R Knezevich; Margaret S Pepe; Patricia A Carney; Linda J Titus; Tracy Onega; Anna N A Tosteson; Martin A Weinstock; Joann G Elmore
Journal:  J Am Acad Dermatol       Date:  2018-03-07       Impact factor: 11.527

5.  Population-Based Analysis of Histologically Confirmed Melanocytic Proliferations Using Natural Language Processing.

Authors:  Jason P Lott; Denise M Boudreau; Ray L Barnhill; Martin A Weinstock; Eleanor Knopp; Michael W Piepkorn; David E Elder; Steven R Knezevich; Andrew Baer; Anna N A Tosteson; Joann G Elmore
Journal:  JAMA Dermatol       Date:  2018-01-01       Impact factor: 10.282

6.  Variation among pathologists' treatment suggestions for melanocytic lesions: A survey of pathologists.

Authors:  Kachiu C Lee; Sue Peacock; Martin A Weinstock; Ge Alice Zhao; Stevan R Knezevich; David E Elder; Raymond L Barnhill; Michael W Piepkorn; Lisa M Reisch; Patricia A Carney; Tracy Onega; Jason P Lott; Joann G Elmore
Journal:  J Am Acad Dermatol       Date:  2016-09-28       Impact factor: 11.527

Review 7.  The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.

Authors:  Boris C Bastian
Journal:  Annu Rev Pathol       Date:  2014       Impact factor: 23.472

8.  Risk of Subsequent Cutaneous Melanoma in Moderately Dysplastic Nevi Excisionally Biopsied but With Positive Histologic Margins.

Authors:  Caroline C Kim; Elizabeth G Berry; Michael A Marchetti; Susan M Swetter; Geoffrey Lim; Douglas Grossman; Clara Curiel-Lewandrowski; Emily Y Chu; Michael E Ming; Kathleen Zhu; Meera Brahmbhatt; Vijay Balakrishnan; Michael J Davis; Zachary Wolner; Nathaniel Fleming; Laura K Ferris; John Nguyen; Oleksandr Trofymenko; Yuan Liu; Suephy C Chen
Journal:  JAMA Dermatol       Date:  2018-12-01       Impact factor: 10.282

9.  Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.

Authors:  P Rudolph; T Lappe; C Schubert; D Schmidt; R M Parwaresch; E Christophers
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

10.  Pathologists' agreement on treatment suggestions for melanocytic skin lesions.

Authors:  Mustufa A Jafry; Sue Peacock; Andrea C Radick; Hannah L Shucard; Lisa M Reisch; Michael W Piepkorn; Stevan R Knezevich; Martin A Weinstock; Raymond L Barnhill; David E Elder; Kathleen F Kerr; Joann G Elmore
Journal:  J Am Acad Dermatol       Date:  2019-12-17       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.